Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.
Summit Therapeutics 'taking leadership role' in development of new antibiotics
Quick facts: Summit Therapeutics PLC
Price: 21 GBX
Market Cap: £70.59 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE